U.S. Food Stock News

In December 2025, Celldex Therapeutics began a global Phase 3 EMBARQ-ColdU and SD trial of barzolvolimab in adults with cold urticaria and symptomatic dermographism who remain symptomatic despite H1 antihistamines or biologics, enrolling about 240 patients across approximately 75 sites in 7 countries with complete response at Week 12 as the primary endpoint. This late-stage program builds directly on earlier placebo-controlled Phase 2 data showing rapid, durable clinical responses and...

Serenity Capital’s decision to lift New Oriental Education & Technology Group (NYSE:EDU) into its top holdings is a clear vote of confidence in the company’s post crack down transformation and earnings trajectory. See our latest analysis for New Oriental Education & Technology Group. That conviction lines up with the market’s tone, with a 30 day share price return of 7.42 percent and a three year total shareholder return of 47.27 percent suggesting momentum is rebuilding after a tougher...

Alvotech (NasdaqGM:ALVO) stock has been under pressure after the FDA issued a Complete Response Letter related to deficiencies at its Reykjavik manufacturing site, which forced the company to cut 2025 revenue and EBITDA guidance. See our latest analysis for Alvotech. Those manufacturing setbacks and shareholder investigations have clearly reset expectations, with the 90 day share price return of minus 38.83 percent and year to date share price return of minus 62.77 percent showing momentum is...

NIO (NIO) just hit its 30,000th ES8 delivery barely three months after launch, even while juggling chip and battery shortages, and that rapid scale up is exactly what has analysts rethinking the stock’s trajectory. See our latest analysis for NIO. That milestone caps a choppy year in the market, with NIO’s share price at $4.99 and a positive year to date share price return, but a weak 3 year total shareholder return signalling momentum is only tentatively rebuilding as investors weigh rapid...

Universal Corporation recently entered into a new bank credit agreement that took effect on December 9, 2025, establishing a US$1.40 billion senior unsecured facility comprising a five-year US$780 million revolving credit line, a funded US$275 million five-year term loan, and a funded US$345 million seven-year term loan, replacing its prior US$1.15 billion facility. This expanded mix of longer-dated term loans and a larger revolving facility increases Universal’s financial flexibility,...

Camden Property Trust (CPT) just packed three catalysts into one stretch: a fresh NYSE Texas dual listing, higher 2025 guidance, and a JP Morgan upgrade, all reshaping how investors are sizing up the stock. See our latest analysis for Camden Property Trust. Those catalysts arrive after a choppy stretch, with the share price at $107.28 and a negative year to date share price return but a positive five year total shareholder return suggesting longer term momentum is still intact even as near...

Thermo Fisher Scientific recently enrolled the first patient in its international PPD CorEvitas Alzheimer’s Disease Registry and introduced new Gibco Bacto CD Supreme formulations to streamline E. coli-based plasmid DNA and protein production for gene therapies and mRNA vaccines. Together, these moves deepen Thermo Fisher’s role in real-world evidence generation for neurodegenerative disease and in high-quality bioprocessing inputs that underpin emerging advanced therapies. Next, we’ll...

Oculis Holding AG recently advanced its neuro-ophthalmology candidate privosegtor (OCS-05) toward registrational PIONEER trials after a positive FDA meeting, while also preparing additional clinical studies for licaminlimab in dry eye disease. This progression signals an effort to build a differentiated ophthalmology pipeline spanning retinal, inflammatory, and neuroprotective conditions with potentially precision-focused therapies. We’ll now examine how advancing privosegtor into late-stage...

In November 2025, Tradeweb Markets reported record total trading volume of US$56.80 trillion and average daily volume of US$2.90 trillion, alongside completing the industry’s first fully electronic on-chain auction for brokered certificates of deposit with Alphaledger’s blockchain technology. These milestones underline how Tradeweb is deepening the electronification of fixed income markets and using blockchain to streamline traditionally manual workflows in bond trading. We’ll explore how...

Dynatrace (DT) just tightened its ties with Google Cloud, stepping in as a launch partner for Gemini CLI extensions and Gemini Enterprise, and that move could subtly reshape how investors think about its AI growth story. See our latest analysis for Dynatrace. That deeper Google Cloud tie up lands after a strong earnings beat and expanded AWS integrations. Yet the share price has a roughly 19% year to date share price decline and three year total shareholder return of about 18%, suggesting...

In December 2025, Rocket Lab Corporation won an up to US$805 million prime contract from the U.S. Space Development Agency to build 18 missile-warning and tracking satellites and also completed the STP-S30 mission for the U.S. Space Force five months ahead of schedule. Together with fresh civil and international wins, these developments mark Rocket Lab’s shift from a small-launch specialist toward a vertically integrated national-security space contractor. We’ll now examine how Rocket...

Earlier this month, SPIE announced a three-year renewable European framework agreement with Tesla to deploy Megapack-based battery energy storage systems, covering engineering, grid connections, and commissioning across its specialist subsidiaries. The deal underlines Tesla’s push to monetise its energy technology beyond vehicles, as grid-scale storage becomes more important for integrating renewable power and maintaining network stability. We’ll now examine how Musk’s renewed pay package...

Hawaiian Electric Industries (HE) is back in focus as it prepares to join the S&P SmallCap 600 on December 22, 2025, even while Maui wildfire litigation and clean energy investments shape its longer term risk profile. See our latest analysis for Hawaiian Electric Industries. The stock has been choppy lately, with a 1 day share price return of minus 6.24 percent, but a year to date share price return of 20.85 percent suggests tentative momentum as investors weigh wildfire liabilities against...

Earlier this week, Amazon announced new Business Prime benefits that include discounted access to Intuit’s QuickBooks Online Simple Start, alongside offers from CrowdStrike and Gusto, aimed at helping small and midsize businesses manage finances, cybersecurity, and HR more efficiently. A separate multi-year partnership with Circle to integrate USDC stablecoin infrastructure across Intuit’s platforms positions the company to modernize payments and refunds with faster, lower-cost, programmable...

First Horizon (FHN) has been quietly grinding higher, with the stock up about 2% in the past day, 4% this week, and roughly 12% over the past month as investors revisit regional banks. See our latest analysis for First Horizon. Zooming out, First Horizon’s share price has climbed steadily this year, with a strong year to date share price return and a solid one year total shareholder return suggesting momentum is quietly rebuilding as investors reassess regional bank risk and growth...

In December 2025, MyOme announced a collaboration and investment from Illumina to support its Proactive Health Trial, which will test whole-genome sequencing combined with AI-integrated risk models across common, chronic, and rare diseases, with enrollment expected to start in 2026. This partnership links Illumina’s population-scale sequencing capabilities with MyOme’s AI-driven risk assessment tools, highlighting a push toward earlier, more personalized interventions that aim to cut a very...

Martin Marietta Materials (MLM) has quietly kept climbing, with shares up about 5% over the past month and nearly 24% this year, as investors focus on steady infrastructure and construction demand. See our latest analysis for Martin Marietta Materials. At around $633.94 a share, that solid year to date share price return of roughly 24% and a three year total shareholder return near 91% suggest investors are steadily pricing in durable infrastructure growth rather than a one quarter story. If...

If you are looking at Venture Global and wondering whether the recent slump has quietly turned it into a value play, you are not alone. The stock has bounced 3.3% over the last week even after a steep 12.4% drop over 30 days and a bruising 73.5% slide year to date. This combination often signals the market is rapidly reassessing both its growth prospects and risk profile. Recent headlines around Venture Global have centered on shifting investor sentiment in the LNG and broader energy space,...

LendingClub (LC) just delivered a stronger quarter, with revenue and net income up solidly from last year, and that combination of earnings momentum and heavy loan demand is starting to reshape how investors view the stock. See our latest analysis for LendingClub. The upbeat quarter lands on top of an already strong run, with a roughly 21.8% year to date share price return and a powerful three year total shareholder return of about 126.6% suggesting momentum is firmly building. If...

If you are wondering whether CME Group is still worth buying after its long run, or if the market has already priced in the upside, you are not alone. That is exactly what we are going to unpack here. The stock has slipped around 1.6% over the last week and 1.5% over the past month, but it is still up 15.6% year to date and 17.8% over the last year, with multi year returns above 78% over three years and 82.2% over five years. Recent market attention has centered on CME as a key beneficiary...

The latest joint venture acquisition of the 195,000 square foot Springs Plaza center in Bonita Springs puts Phillips Edison (PECO) back in focus and highlights how it is leaning into high growth, necessity retail markets. See our latest analysis for Phillips Edison. That Springs Plaza deal slots neatly into a year where momentum has been steady rather than spectacular, with a modest positive multi month share price return and a solid three year total shareholder return of 25 percent...

Evolv Technologies Holdings (EVLV) is back in the spotlight after announcing its Evolv Express systems are being installed at the 14,000 seat Pechanga Arena San Diego, further extending its footprint across major California venues. See our latest analysis for Evolv Technologies Holdings. That expanding customer list seems to be feeding into sentiment, with the share price at $7.21 and a strong year to date share price return alongside a robust one year total shareholder return, suggesting...

Amgen (AMGN) just checked two big boxes at once, tightening its partnership with Washington on drug pricing while winning FDA approval for UPLIZNA in generalized myasthenia gravis, and the stock is reacting accordingly. See our latest analysis for Amgen. That backdrop of tariff relief and drug price cooperation, combined with the fresh UPLIZNA approval, comes on top of a strong run, with Amgen’s share price up 26.27% year to date and a 5 year total shareholder return of 71.89%, which suggests...

Celanese (CE) has had a choppy year in the market, with the stock sliding sharply year to date even as revenue edges higher and net income rebounds from a deep loss. Investors are now reassessing what that disconnect really means. See our latest analysis for Celanese. At around $42.29 per share, Celanese’s 11.49% 1 month share price return looks like a short term bounce within a much tougher backdrop. The 5 year total shareholder return is still deeply negative and momentum appears more...